Purple Biotech Ltd. (PPBT) stock
PPBTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.56+0.07 (+4.70%)
Close on Nov 12, 2026Market cap $1.45MP/E 0.0Yield –
Purple Biotech EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was $0.03, down 99.5% from the year before. Over ten years it grew -39.9% a year on average. The highest annual figure on record is $17568036.00 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.03 | -99.5% |
| FY2024 | Dec 31, 2024 | $4.99 | -72.2% |
| FY2023 | Dec 31, 2023 | $17.96 | -25.1% |
| FY2022 | Dec 31, 2022 | $23.97 | -100.0% |
| FY2021 | Dec 31, 2021 | $17568036.00 | +720001375.4% |
| FY2020 | Dec 31, 2020 | $2.44 | – |
| FY2019 | Dec 31, 2019 | -$3.00 | – |
| FY2018 | Dec 31, 2018 | -$3.90 | -384.7% |
| FY2017 | Dec 31, 2017 | $1.37 | -35.1% |
| FY2016 | Dec 31, 2016 | $2.11 | -52.0% |
| FY2015 | Dec 31, 2015 | $4.40 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?